Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/08 Earnings release - Q1 2027

More about the company

Quotes

Date	Price	Change	Volume
31/07/26	JPY 247.00	+2.49%	45,700
30/07/26	JPY 241.00	+0.42%	43,500
29/07/26	JPY 240.00	+1.27%	61,900
28/07/26	JPY 237.00	-2.47%	63,600
27/07/26	JPY 243.00	-0.41%	82,900

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Market Closed - Japan Exchange Other stock markets 04:30:00 31/07/26 pm AEST			5-day change	1st Jan Change
247.00 ^JPY	+2.49%		+1.23%	-27.35%

17/06	Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
01/06	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI

Market Cap	6.37B 39.98M 34.76M 32.35M 29.7M 56.09M 3.82B 56.96M 381M 150M 1.9B 150M 147M	P/E 2025	49.7x	P/E 2026	-9.95x
Enterprise Value	5.47B 34.33M 29.84M 27.77M 25.5M 48.16M 3.28B 48.9M 327M 128M 1.63B 129M 126M	EV / Sales 2025	6.38x	EV / Sales 2026	33.4x
Free-Float	28.38%	Yield 2025 *	-	Yield 2026	-

17/06	Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
01/06	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
01/06	Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million.	CI
15/05	Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026	CI
15/05	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
13/02	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
13/02	Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
12/05/25	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
17/02/25	Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
20/11/24	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
19/12/22	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022.	CI
20/09/22	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	CI
23/06/22	Tsubota Laboratory Incorporated has completed an IPO in the amount of Ã‘1.8048 billion.	CI

1 day	+2.49%
1 week	+1.23%
1 month	+6.47%
3 months	-15.70%
6 months	-22.33%
Current year	-27.35%

Tsubota Laboratory Incorporated Stock

Stocks

4890

JP3535700003

Biotechnology & Medical Research

Valuation: Tsubota Laboratory Incorporated

Chart: Tsubota Laboratory Incorporated

Latest news : Tsubota Laboratory Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: Tsubota Laboratory Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Kazuo Tsubota PSD	President	71	01/02/2019
Keisuke Mitsuoka ADM	Chief Administrative Officer	-	-
Kenji Morishima CTO	Chief Tech/Sci/R&D Officer	65	01/01/2025

Director	Title	Age	Since
Kazuo Tsubota BRD	Director/Board Member	71	01/02/2019
Shinichi Koizumi BRD	Director/Board Member	70	01/06/2020
Eri Kubota BRD	Director/Board Member	55	01/06/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/11/24	Kazuo Tsubota	Others	Founder	63,000	0.2465%
15/11/24	Kazuo Tsubota	Others	Founder	420,000	1.6434%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TSUBOTA LABORATORY INCORPORATED	+2.49%	+1.23%	-32.70%	-60.03%	39.98M
LONZA GROUP AG	-1.40%	+2.59%	-1.71%	+11.28%	48.53B
REVOLUTION MEDICINES, INC.	-2.41%	-0.90%	+411.96%	+495.33%	39.87B
IQVIA HOLDINGS INC.	-1.16%	+12.96%	+28.81%	+7.25%	38.68B
BEONE MEDICINES AG	-1.88%	-3.03%	+5.69%	+53.00%	35.13B
CELLTRION, INC.	-1.74%	+5.12%	+14.44%	+41.77%	29.79B
MEDPACE HOLDINGS, INC.	-0.21%	-4.04%	+36.40%	+125.75%	16.11B
ASCENDIS PHARMA A/S	-2.85%	-3.92%	-	-	16.08B
EUROFINS SCIENTIFIC SE	-0.64%	+2.65%	+3.40%	+13.11%	13.61B
ICON PUBLIC LIMITED COMPANY	-1.19%	-1.32%	-1.73%	-34.37%	12.62B
Average	-1.10%	+1.07%	+51.62%	+72.57%	25.05B
Weighted average by Cap.	-1.60%	+2.03%	+79.76%	+108.59%

	2025	2026
Net sales	1.36B 8.52M 7.4M 6.89M 6.33M 11.95M 813M 12.13M 81.22M 31.88M 405M 31.98M 31.28M	200M 1.26M 1.09M 1.02M 932K 1.76M 120M 1.79M 11.97M 4.7M 59.65M 4.71M 4.61M
Net income	205M 1.29M 1.12M 1.04M 956K 1.8M 123M 1.83M 12.27M 4.82M 61.14M 4.83M 4.73M	-761M -4.78M -4.15M -3.86M -3.55M -6.7M -456M -6.8M -45.55M -17.88M -227M -17.93M -17.54M
Net Debt	-1.45B -9.09M -7.9M -7.35M -6.75M -12.75M -867M -12.94M -86.66M -34.01M -432M -34.13M -33.38M	-901M -5.65M -4.91M -4.57M -4.2M -7.93M -540M -8.05M -53.93M -21.16M -269M -21.23M -20.77M

1 week	235	252
1 month	226	288
Current year	210	478
1 year	210	478
3 years	210	625
5 years	210	1,447
10 years	210	1,447